PRESS RELEASES

Archives

November 3, 2010 - OptiNose Receives Nearly $489,000 Grant Award Under U.S. Government Qualifying Therapeutic Discovery Project Program

October 28, 2010 - Rapid Absorption Rate Alone May Not Explain Efficacy in Migraines of Sumatriptan Delivered with OptiNose’s Novel Drug Delivery Technology

October 20, 2010 - New Data Show Therapeutic Benefits in Chronic Rhinosinusitis Patients Using Fluticasone Delivered by OptiNose’s Novel Delivery Technology

August 10, 2010 - OptiNose Announces Publication of Positive Subgroup Analysis Evaluating Efficacy of Fluticasone Delivered with Novel Drug Delivery Technology

June 7, 2010 - Avista Capital Partners Commits $48.5 Million to OptiNose to Develop an Innovative Nasal Drug Delivery Technology Slated to Begin Phase III Trials